Tumor Slice Culture: A New Avatar in Personalized Oncology
Technical Report,01 Sep 2017,31 Aug 2018
University of Washington Seattle United States
Pagination or Media Count:
Despite the promise of personalized medicine to define the precise genetic landscape of each cancer, there remains an enormous gap between our knowledge of the genomic alterations harbored by a tumor, and how these changes affect the biology of the cancer and its response to drugs. In other words, there is a missing link between the scientific world of cancer genetics and the clinical world of therapeutic decisions. To bring us closer towards the goal of tailoring effective therapy for individual cancer i.e. personalized oncology, we will establish a new platform for testing drug sensitivity outside the body, using tissues directly obtained from the patients cancer in the form of a slice culture. Pieces of human cancers will be kept alive in an incubator for days without significant detriment to their viability. During this period, we will test a variety of drugs and cell-based therapies to determine their effects on the specific tumors. Unlike other forms of human cancer models, our Tumor Slice Culture TSC system utilizes a standardized easy-to-follow protocol to come up with results that are reproducible and clinically relevant in a very short timeframe compared to other methods e.g. 2 weeks vs. 3-6 months. Consequently, we feel strongly that our TSC platform will aid physicians in their decision making and lead to more effective cancer therapy, while minimizing the toxicities and expense of ineffective drugs.
- Medicine and Medical Research